Evidence map›Paper›PMID 27324127›Full record

ReviewCell and tissue research2016

Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration.

Virpi Talman, Heikki Ruskoaho

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in Cell and tissue research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05531955 (A Study of Pirfenidone in the Treatment of Myocardial Fibrosis After Acute Myocardial Infarction), which is not on this map. Cited by 494 papers.

0numbers the graph read from it
0cells of the map it votes in
494citing papers in PubMed
37.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05531955 phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

A Study of Pirfenidone in the Treatment of Myocardial Fibrosis After Acute Myocardial Infarction: a Phase II Prospective, Randomized, Double-blind,Placebo Controlled Clinical Trial

TypeinterventionalSponsorShanghai Zhongshan HospitalRan2022 to 2024Enrolled100ConditionsMyocardial FibrosisArmsPirfenidone Oral Capsule, Placebo Oral Capsule
3 · Its place in the literature

Who cites it

494 citing papers in PubMed, 872 citations in OpenAlex.

  1. Efficacy and safety of levosimendan in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: The LEVOCEST trial.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2024
    Trial
  2. Multi-modality deep learning-based [European journal of nuclear medicine and molecular imaging · 2024
    Trial
  3. Article
  4. Early post-infarct fibroblast activation protein-targeted PET/CT withEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Gfpt2 modulates fibroblast activation by glutathione metabolism.Journal of molecular and cellular cardiology · 2026
    Article
  6. Article
  7. Article
  8. An integrated overview of acute heart failure: a narrative review of pathophysiological mechanisms and contributing factors.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Review
  9. Review
  10. Article
  11. Collagen Prolyl 4-Hydroxylase: An Emerging Key Player in Cardiac Fibrosis.Journal of cardiovascular translational research · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

434 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Virpi TalmanDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014, Helsinki, Finland. virpi.talman@helsinki.fi.
Heikki RuskoahoDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, P.O. Box 56, FI-00014, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic cell death during a myocardial infarction leads to a multiphase reparative response in which the damaged tissue is replaced with a fibrotic scar produced by fibroblasts and myofibroblasts. This also induces geometrical, biomechanical, and biochemical changes in the uninjured ventricular wall eliciting a reactive remodeling process that includes interstitial and perivascular fibrosis. Although the initial reparative fibrosis is crucial for preventing rupture of the ventricular wall, an exaggerated fibrotic response and reactive fibrosis outside the injured area are detrimental as they lead to progressive impairment of cardiac function and eventually to heart failure. In this review, we summarize current knowledge of the mechanisms of both reparative and reactive cardiac fibrosis in response to myocardial infarction, discuss the potential of inducing cardiac regeneration through direct reprogramming of fibroblasts and myofibroblasts into cardiomyocytes, and review the currently available and potential future therapeutic strategies to inhibit cardiac fibrosis. Graphical abstract Reparative response following a myocardial infarction. Hypoxia-induced cardiomyocyte death leads to the activation of myofibroblasts and a reparative fibrotic response in the injured area. Right top In adult mammals, the fibrotic scar formed at the infarcted area is permanent and promotes reactive fibrosis in the uninjured myocardium. Right bottom In teleost fish and newts and in embryonic and neonatal mammals, the initial formation of a fibrotic scar is followed by regeneration of the cardiac muscle tissue. Induction of post-infarction cardiac regeneration in adult mammals is currently the target of intensive research and drug discovery attempts.

Indexed as

RegenerationVascular RemodelingWound HealingAnimalsFibrosisHumansMyocardial InfarctionMyocardiumAnti-fibrotic therapyCardiac fibrosisCardiac regenerationMyocardial infarctionPro-fibrotic signaling

Identifiers

PMID27324127
PMCPMC5010608
OpenAlexW2462759503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.